Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00759330 · ClinicalTrials.gov registry record · Phase 2

Flurbiprofen Tape for Treatment of Chronic Low Back Pain

A Phase 2 study, sponsored by Teikoku Pharma USA.

Completed
Registry status
Phase 2
Development phase
127
Enrollment target

NCT00759330: Completed Phase 2 study, sponsored by Teikoku Pharma USA.

NCT00759330 is a Phase 2 study that has completed, run by Teikoku Pharma USA. The registered enrollment target is 127 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00759330, a Phase 2 study, has completed, sponsored by Teikoku Pharma USA.

COMPLETED
Registry status
Phase 2
Development phase
127 participants
Enrollment target

Study Summary

The purpose of this trial is to evaluate the analgesic efficacy and safety of flurbiprofen tape for chronic low back pain (lasting greater than 3 months).

Primary Outcome

The primary efficacy endpoint was the cumulative summed pain intensity difference (SPID+) at Days 4 and 7 of the tape treatment phase as computed from the daily categorical pain scale score reported on the patient's daily diary during the tape treatment phase; pain was rated on an 11-point scale, where: 0 = no pain, 10 = worst pain imaginable. Summed pain intensity difference is the sum of the pain intensity differences (PID). PID at each post-baseline evaluation was computed as the average bas

Interventions

  • DRUG Placebo Tape (Arm 1)
  • DRUG Flurbiprofen Tape (Arm 2)
  • DRUG Placebo Tape (Arm 3)
  • DRUG Flurbiprofen Tape (Arm 4)

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2007-10
Est. Completion 2008-07
Phase Phase 2
Teikoku Pharma USA

5 total trials

What the finished NCT00759330 record still lists

NCT00759330 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 4 interventions - of which Placebo Tape (Arm 1) is the first listed.

NCT00759330 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00759330 about?

NCT00759330 is a clinical study titled "Flurbiprofen Tape for Treatment of Chronic Low Back Pain". The purpose of this trial is to evaluate the analgesic efficacy and safety of flurbiprofen tape for chronic low back pain (lasting greater than 3 months).

What is the current status of trial NCT00759330?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2007-10. Estimated completion is 2008-07.

What interventions are being tested in trial NCT00759330?

The interventions under investigation include: Placebo Tape (Arm 1) (DRUG), Flurbiprofen Tape (Arm 2) (DRUG), Placebo Tape (Arm 3) (DRUG), Flurbiprofen Tape (Arm 4) (DRUG).

Who is sponsoring clinical trial NCT00759330?

This trial is sponsored by Teikoku Pharma USA, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00759330's enrollment target sits among peer trials

127 555th of 2000 higher than 1,445 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03017820 · 127 participants · Phase 1

    A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

  • NCT03609580 · 127 participants · Phase 1

    Post-operative Urinary Retention (POUR) Following Thoracic Surgery

  • NCT06285643 · 127 participants · Phase 2

    A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

  • NCT06809400 · 127 participants · Phase 1

    A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00759330, the US trial registry maintained by the National Library of Medicine. NCT00759330 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.